Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.

JCO precision oncology - 1 Jun 2022

Liu Minetta C, MacKay Matthew, Kase Matthew, Piwowarczyk Aneta, Lo Christine, Schaeffer Jeff, Finkle Justin D, Mason Christopher E, Beaubier Nike, Blackwell Kimberly L, Park Ben Ho

Abstract excerpt

Tissue-based next-generation sequencing (NGS) in metastatic breast cancer (mBC) is limited by the inability to noninvasively track tumor evolution. Cell-free DNA (cfDNA) NGS has made sequential testing feasible; however, the relationship between cfDNA and tissue-based testing in mBC is not well understood. Here, we evaluate concordance between tissue and cfDNA NGS relative to cfDNA sampling frequency in a large,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35721584
DOI: 10.1200/PO.21.00321
PMCID: PMC9200387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.PMID 35721584Read ↗

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.Semantic proximity Read ↗

Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast CancerSemantic proximity Read ↗

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.Semantic proximity Read ↗

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.Semantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.Semantic proximity Read ↗

Next-generation sequencing in breast cancer: current clinical applications and future directionsSemantic proximity Read ↗

Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis.Semantic proximity Read ↗

Dissecting Tumor Heterogeneity by Liquid Biopsy—A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid NeoplasiasSemantic proximity Read ↗

Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.Semantic proximity Read ↗

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Semantic proximity Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.